Monitor for actual sales filings (Form 4) in the coming weeks to confirm if and when the shares are sold. Officer-level sales are routine but should be watched for unusual volume or timing relative to company catalysts.
EWTX drugs
EWTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 30 $30.28entry
- T+1 · 8mo ago +4.03%α +1.14% · $31.50
- T+5 · 7mo ago +7.33%α +3.03% · $32.50
- T+20 · 7mo ago +2.34%α −10.25% · $30.99
- T+60 · 5mo ago +37.68%α +21.19% · $41.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Joanne Donovan, an officer of Edgewise Therapeutics, filed a Form 144 to notify intent to sell up to 71,588 shares of common stock. The shares were acquired through stock option exercises, an employee stock purchase plan, and restricted stock unit vesting.
Key Facts
- Joanne Donovan, an officer of Edgewise Therapeutics, intends to sell up to 71,588 shares.
- The shares consist of 50,000 from stock option exercises, 9,623 from an employee stock purchase plan, and 11,965 from restricted stock unit vesting.
- The filing was submitted on March 27, 2026, with the sales expected to occur over the next three months.
- No immediate sale has been reported; this is a notice of proposed sale.
Financial Impact
Approximately $2.27 million based on 71,588 shares at $31.70 per share (implied from filing data)
Risk Factors
- Perception of insider selling could weigh on investor sentiment, especially if sales occur near key company events.
- If the sales proceed, it may indicate reduced insider confidence, though the shares are from routine compensation vesting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003048 |
| Document: 0001950047-26-003048-index.html | 0001950047-26-003048 |
| Document: 0001950047-26-003048.txt | 0001950047-26-003048 |
Track record
14 reports on EWTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 144 Neutral 1/10 Entry price pending
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
- Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
- Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
- Jun 1, 202624w ago 8-K Bullish 8/10 Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers